Catherine Tsilfidis

Catherine Tsilfidis

PhD

Senior Scientist Emeritus, Neuroscience

Ottawa Hospital Research Institute

Associate Professor, Departments of Ophthalmology and Cellular and Molecular Medicine

Faculty of Medicine

Former Assistant Dean, Office of Equity

Diversity and Inclusion

Bio

Catherine Tsilfidis is a senior scientist in the Neuroscience Program of the Ottawa Hospital Research Institute, and an Associate Professor in the Departments of Ophthalmology and Cellular and Molecular Medicine at the University of Ottawa. Her research is aimed at developing a gene therapy strategy that blocks apoptosis and slows down retinal disease progression. She has applied this approach to the treatment of animal models of retinal disease. Her laboratory is currently optimizing gene therapy parameters for application to human disease.

Dr. Tsilfidis is also the former Assistant Dean of the Office of Equity, Diversity and Inclusion (EDI) in the Faculty of Medicine at the University of Ottawa. She organized and delivered workshops to medical students, residents, graduate students and faculty on harassment and intimidation, respect in the workplace, and unconscious bias. Dr. Tsilfidis is passionate about promoting the advancement of underrepresented groups in science and continues to be involved in EDI advisory roles.

Research Goals and Interests

Retinal diseases, retinal gene therapy, apoptosis of retinal cells as a cause for retinal disease, anti-apoptotic strategies for preserving retinal cells and delaying retinal disease progression

Inherited retinal degenerations lead to a progressive loss of vision. Most often, they are characterized by a gradual loss of the photoreceptors in the retina. Cell death occurs through the process of apoptosis. We believe that regardless of the genetic mutation which a cell possesses, if we can target and prevent the ultimate death of the cell, we will be able to retain function in the retina and prevent vision loss. We are using inhibitors of apoptosis (IAPs) to try to prevent the retinal degeneration which is associated with diseases such as retinitis pigmentosa, retina&nbspischemia, or Leber's Hereditary Optic Neuropathy (LHON). The X-linked inhibitor of apoptosis (XIAP) protein prevents apoptosis by blocking the action of caspases, which are enzymes that are involved in the cell death pathway. Delivery of XIAP to the retina using adeno-associated virus results in efficient infection of retinal cells and leads to over-expression of XIAP in the target cells. We have used this approach to show that XIAP protects photoreceptors in animal models of chemotoxic damage, retinal ischemia, and retinitis pigmentosa. Our current studies are aimed at developing this therapeutic strategy for application to human retinal disease.


News


Publications

Assessment of the uniform field electroretinogram for mouse retinal ganglion cell functional analysis

2023-08-01 Go to publication

XIAP gene therapy effects on retinal ganglion cell structure and function in a mouse model of glaucoma

2022-04-01 Go to publication

Related Research at The Ottawa Hospital